Bart L. Scott

Oncology

1959 NE Pacific St
Seattle, WA 98195

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 138 publications

Randomized phase 2 trial of CPX-351 vs. CLAG-M (cladribine, cytarabine, G-CSF, and mitoxantrone) for medically unfit adults with acute myeloid leukemia or other high-grade myeloid neoplasms.

Randomized phase 2 trial of CPX-351 vs. CLAG-M (cladribine, cytarabine, G-CSF, and mitoxantrone) for medically unfit adults with acute myeloid leukemia or other high-grade myeloid neoplasms.

Journal: Leukemia

Published: January 16, 2026

PTCy or ATG for Matched Transplantation in Myelofibrosis.

PTCy or ATG for Matched Transplantation in Myelofibrosis.

Journal: American journal of hematology

Published: January 03, 2026

Nonmyeloablative conditioning combined with the anti-CD117 antibody briquilimab in older adults with high-risk AML and MDS.

Nonmyeloablative conditioning combined with the anti-CD117 antibody briquilimab in older adults with high-risk AML and MDS.

Journal: Blood

Published: November 10, 2025

Nonmyeloablative Conditioning Combined with Anti-CD117 Antibody Briquilimab in Older Adults with High-Risk AML and MDS.

Nonmyeloablative Conditioning Combined with Anti-CD117 Antibody Briquilimab in Older Adults with High-Risk AML and MDS.

Journal: Blood

Published: November 10, 2025

Pre-Hematopoietic Cell Transplantation Ruxolitinib in Transplantation-Eligible Patients with Myelofibrosis: Long-Term Outcomes of a Phase II Prospective Study.

Pre-Hematopoietic Cell Transplantation Ruxolitinib in Transplantation-Eligible Patients with Myelofibrosis: Long-Term Outcomes of a Phase II Prospective Study.

Journal: Transplantation and cellular therapy

Published: July 21, 2025

A cure for the kiss of death?

A cure for the kiss of death?

Journal: Blood advances

Published: June 10, 2025

Defining remission following hematopoietic cell transplant for myelofibrosis: an international expert panel consensus.

Defining remission following hematopoietic cell transplant for myelofibrosis: an international expert panel consensus.

Journal: Leukemia

Published: May 13, 2025

Advancing drug development in myelodysplastic syndromes.

Advancing drug development in myelodysplastic syndromes.

Journal: Blood advances

Published: September 20, 2024

Role of molecular alterations in transplantation decisions for patients with primary myelofibrosis.

Role of molecular alterations in transplantation decisions for patients with primary myelofibrosis.

Journal: Blood advances

Published: July 29, 2024

Change is not always good.

Change is not always good.

Journal: Blood

Published: July 25, 2024

Consistency of Spleen and Symptom Reduction Regardless of Cytopenia in Patients With Myelofibrosis Treated With Pacritinib.

Consistency of Spleen and Symptom Reduction Regardless of Cytopenia in Patients With Myelofibrosis Treated With Pacritinib.

Journal: Clinical lymphoma, myeloma & leukemia

Published: May 23, 2024

Donor types and outcomes of transplantation in myelofibrosis: a CIBMTR study.

Donor types and outcomes of transplantation in myelofibrosis: a CIBMTR study.

Journal: Blood advances

Published: April 22, 2024

Showing 1-12 of 138

Last Updated: 09/26/2026